在心脏骤停后AT1受体阻塞对心血管结果的影响:在老鼠身上进行的一项实验研究
E A F Araújo Filho1, M J C Carmona2, D A Otsuki3
1Departamento de Cirurgia (LIM 08), Faculdade de Medicina da USP (FMUSP), EAF: Av. Dr. Arnaldo, 455, sala 2120 (LIM-08), São Paulo, SP, 01246-903, Brazil. elsonfilho2@hotmail.com.
Scientific reports
|October 25, 2023
概括
坎德沙坦 (candesartan) 等抗胰岛素II受体1 (AT1) 阻断剂可以提高存活率,并减少心脏骤停后器官损伤. 这项研究表明,AT1受体阻塞增强了自发循环 (ROSC) 的恢复,并保护了大脑和心脏组织.
科学领域:
- 心血管研究研究心血管研究
- 神经科学是一个神经科学.
- 药理学 药理学 是一个学科.
背景情况:
- 众所周知, ангиотензинII受体1 (AT1) 抗剂在焦点缺血症/再输液损伤中具有有益作用.
- 在全球性缺血/再输血中AT1抑制剂的疗效,特别是在心脏骤停 (CA) 之后,仍然在很大程度上未被探索.
研究的目的:
- 为了研究使用candesartan对AT1受体阻塞的潜在益处,在由心脏骤停引起的全球性缺血/再输的小鼠模型中.
- 评估坎德沙坦对存活率,血液动力学变量以及心脏骤停后神经元和心脏损伤组织学标记物的影响.
主要方法:
- 威斯塔雄性大鼠经历了诱导的心脏骤停 (3分钟) 和无氧 (5分钟),随后进行心肺复苏.
- 动物被分为四组:控制 (CA),AT1抗剂 (candesartan),载体 (DMSO) 和Sham.
- 自发循环 (ROSC) 恢复后长达4小时评估的结果包括生存率,血液动力学和组织病理学.
主要成果:
- 与对照组相比,康德沙坦治疗组 (GAT1) 的ROSC率 (62.5%与42.1%) 和存活率 (100%与62.5%) 显著更高.
- 在GAT1中,ROSC后心律失常的发病率较低 (10%比62.5%),在组织学评估中神经元和心脏损伤得分降低 (p<0.05).
- 两组之间在CA持续时间,上腺素剂量或除尝试方面没有发现显著差异.
结论:
- 坎德沙坦的AT1受体阻塞显著改善了大鼠心脏骤停全球性缺血/再输后的结果.
- 康德沙坦的使用提高了复苏成功率 (ROSC) 和生存率.
- 该治疗提供了显著的神经保护和心脏保护,减少心脏骤停后的组织损伤.
相关概念视频
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
752
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
752
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
438
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
438
01:17Antihypertensive Drugs: Action of β1 Blockers
456
β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this,...
456
01:22Heart Failure Drugs: β-Blockers
346
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
346
01:25Cardiopulmonary Resuscitation IV: Pharmacological Management
12
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
12
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
496
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
496